Avanos Medical (NYSE:AVNS) Updates FY 2025 Earnings Guidance

Avanos Medical (NYSE:AVNS) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.850-0.950 for the period, compared to the consensus earnings per share estimate of 0.850. The company issued revenue guidance of $690.0 million-$700.0 million, compared to the consensus revenue estimate of $679.6 million.

Avanos Medical Trading Up 0.7%

NYSE:AVNS traded up $0.08 during midday trading on Friday, reaching $11.26. 635,170 shares of the stock traded hands, compared to its average volume of 544,831. The stock has a market capitalization of $522.32 million, a P/E ratio of -1.10 and a beta of 1.19. The company has a fifty day moving average of $11.70 and a 200 day moving average of $11.92. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.58 and a current ratio of 2.38. Avanos Medical has a 12 month low of $9.30 and a 12 month high of $21.12.

Avanos Medical (NYSE:AVNS) last announced its earnings results on Wednesday, November 5th. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.10. Avanos Medical had a negative net margin of 67.00% and a positive return on equity of 6.21%. The firm had revenue of $177.80 million for the quarter, compared to analyst estimates of $164.50 million. During the same quarter in the previous year, the firm posted $0.33 EPS. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. On average, research analysts predict that Avanos Medical will post 1.32 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Wall Street Zen cut Avanos Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avanos Medical in a report on Tuesday, October 14th. Finally, Zacks Research raised shares of Avanos Medical to a “hold” rating in a research note on Tuesday, August 12th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce”.

Insider Activity at Avanos Medical

In other news, Director Gary Blackford bought 40,000 shares of the business’s stock in a transaction dated Wednesday, August 13th. The stock was purchased at an average cost of $10.99 per share, with a total value of $439,600.00. Following the acquisition, the director directly owned 40,000 shares in the company, valued at $439,600. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.64% of the stock is owned by insiders.

Hedge Funds Weigh In On Avanos Medical

Institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. raised its stake in shares of Avanos Medical by 969.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock worth $31,000 after buying an additional 2,307 shares during the period. Tower Research Capital LLC TRC raised its position in Avanos Medical by 433.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock worth $77,000 after acquiring an additional 5,083 shares during the period. State of Wyoming lifted its holdings in Avanos Medical by 64.4% during the second quarter. State of Wyoming now owns 17,273 shares of the company’s stock valued at $211,000 after purchasing an additional 6,765 shares in the last quarter. Cerity Partners LLC purchased a new position in Avanos Medical during the second quarter valued at $272,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Avanos Medical by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock valued at $386,000 after purchasing an additional 1,121 shares during the period. Hedge funds and other institutional investors own 95.17% of the company’s stock.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.